ERBB2 and cancer: Until recently, almost all studies of HER2 status focused on one type of malignancy, making it difficult to compare the rate of HER2 positivity across studies and tumor types.36-40 Furthermore, HER2 overexpression or amplification is most often evaluated by IHC or FISH, rather than NGS.41,42 However, in the current era of personalized cancer therapy, NGS is becoming more widely used.